Navigation Links
GeneCards(R) Version 3.0 Beta Released
Date:5/13/2009

CAMBRIDGE, Mass., May 13 /PRNewswire/ -- Xennex, Inc. (Xennex) announced today a major leap for GeneCards(R) with the release of Version 3.0 beta, available at http://www.genecards.org/v3.

The new GeneCards Version 3.0 features a significantly upgraded infrastructure, including a comprehensive relational biological database, and a novel, sophisticated and speedier search engine. It provides capabilities for highly effective and well-targeted queries, a user-friendly display and clear data navigation. Also released is a preliminary version of GeneDecks Version 3, which makes use of the new GeneCards relational database for complex analyses on sets of genes.

Dr. David Warshawsky, President and CEO of Xennex, stated: "We are delighted to see the outstanding progress resulting from our partnership with the GeneCards team at the Weizmann Institute of Science. GeneCards Version 3.0 is a major milestone that will enable users around the world to better perform cutting-edge research in various fields of biology and medicine, and in the discovery and development of diagnostics and therapeutics."

Xennex is providing its commercial users with access to the new GeneCards Version 3.0 beta relational database. With GeneCards Version 3.0, Xennex' customers will be able to integrate GeneCards data into their internal systems, and perform comprehensive data mining.

About GeneCards(R)

GeneCards(R) (http://www.genecards.org/) is a searchable, integrated database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease-related information on all known and predicted human genes. Information is featured in 18 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, directed by Marilyn Safran and by Professor Doron Lancet of the Department of Molecular Genetics, Head of the Crown Human Genome Center, and the incumbent of the Ralph & Lois Silver Professorial Chair of Human Genomics at the Weizmann Institute of Science.

About Xennex

Founded in 2003, Xennex, Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex' customers include many of the world's leading biotech and pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.

    For further information, please contact:

    Xennex, Inc.
    David Warshawsky, Ph.D.
    Chief Executive Officer
    Tel: +1 617 497 7774
    davidw@xennexinc.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Xennex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization of Protein Biomarkers Associated With Neurological Conditions
2. Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.
3. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
4. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
5. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
6. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
7. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
8. PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace
9. Bio-Tech Medical Software, Inc. Biometrics Joins Forces with the University of Central Florida to Fight Diversion and Help Combat Prescription Narcotic Drug Abuse
10. Medicsight Unveils New Version of ColonCAD(TM) at ECR 2009
11. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE MKT: ... its CEO, Eugene Seymour , MD, MPH, will present information ... at the Waldorf-Astoria Hotel in New York City ... will be in the Windsor Room at 5:30PM EST. Registered attendees ... New York City . --> ...
(Date:2/8/2016)... -- --> --> ... ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it ... test to be launched on the Company,s io® platform. By ... test is now cleared for sale within the European Union. ... of the io® CT test signals a new era in ...
(Date:2/5/2016)... 2016 ATCC, the premier global biological materials ... medical and life science researchers that are working to ... CDC website . --> ... is a single-stranded RNA virus of the Flaviviridae family, ... and Chikungunya Viruses. Zika virus is transmitted to humans ...
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):